keyword
MENU ▼
Read by QxMD icon Read
search

radioactive iodine refractory

keyword
https://www.readbyqxmd.com/read/29779695/successful-treatment-switch-from-lenvatinib-to-sorafenib-in-a-patient-with-radioactive-iodine-refractory-differentiated-thyroid-cancer-intolerant-to-lenvatinib-due-to-severe-proteinuria
#1
Hideaki Goto, Naomi Kiyota, Naoki Otsuki, Yoshinori Imamura, Naoko Chayahara, Hirotaka Suto, Yoshiaki Nagatani, Masanori Toyoda, Toru Mukohara, Ken-Ichi Nibu, Toshihiko Kasahara, Yasuhiro Ito, Akihiro Miya, Mitsuyoshi Hirokawa, Akira Miyauchi, Hironobu Minami
Sorafenib and lenvatinib showed efficacy for patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC) in pivotal phase 3 clinical trials. Although the efficacy of lenvatinib in patients who received previous treatment with multi-target kinase inhibitors (m-TKIs), including sorafenib, was reported, the efficacy of sorafenib in patients who previously received lenvatinib remains unknown. A 75-year-old woman diagnosed as RAI-refractory poorly differentiated carcinoma with multiple lung metastases and started treatment with lenvatinib...
May 17, 2018: Auris, Nasus, Larynx
https://www.readbyqxmd.com/read/29778126/is-parenteral-levothyroxine-therapy-safe-in-intractable-hypothyroidism
#2
Hande Peynirci, Bengur Taskiran, Erdinc Erturk, Pınar Sisman, Canan Ersoy
CASE: A 32-year old woman was admitted to the hospital due to intractable hypothyroidism refractory to high dose of oral l-thyroxine therapy. She underwent total thyroidectomy and radioactive iodine therapy due to papillary thyroid cancer. After excluding poor adherence to therapy and malabsorption, levothyroxine absorption test was performed. No response was detected. Transient neurologic symptoms developed during the test. She developed 3 attacks consisting of neurologic symptoms during high dose administration...
June 2018: Journal of the National Medical Association
https://www.readbyqxmd.com/read/29702263/a-sorafenib-sparing-effect-in-the-treatment-of-thyroid-carcinoma-cells-attained-by-co-treatment-with-a-novel-isoflavone-derivative-and-1-25-dihydroxyvitamin-d3
#3
Elena Izkhakov, Orli Sharon, Esther Knoll, Asaf Aizic, Dan M Fliss, Fortune Kohen, Naftali Stern, Dalia Somjen
BACKGROUND: Sorafenib improves progression-free survival in patients with progressive radioactive iodine-refractory differentiated thyroid carcinoma, but causes severe side effects. Estrogens may accelerate thyroid carcinoma cell growth. Our group recently reported that isoflavone derivative 7-(O)-carboxymethyl daidzein conjugated to N-t-boc-hexylenediamine (cD-tboc), a novel anti-estrogenic compound, retards the growth of both thyroid carcinoma cell lines and cultured human carcinoma cells...
April 24, 2018: Journal of Steroid Biochemistry and Molecular Biology
https://www.readbyqxmd.com/read/29688947/impact-of-patient-age-and-histological-type-on-radioactive-iodine-avidity-of-recurrent-lesions-of-differentiated-thyroid-carcinoma
#4
Kenichi Nakanishi, Toyone Kikumori, Noriyuki Miyajima, Yuko Takano, Sumiyo Noda, Dai Takeuchi, Shingo Iwano, Yasuhiro Kodera
BACKGROUND: Age is a prognostic factor for recurrent differentiated thyroid carcinoma (DTC) and may be related to radioactive iodine (RAI) nonavidity. Indications for molecular-targeted drugs (MTDs) are currently limited to RAI-refractory DTC. Demonstrating refractoriness to RAI, mainly indicated by RAI nonavidity, may be a barrier to the introduction of MTDs for elderly patients. The present study was conducted to evaluate the impact of age and histological type on the RAI avidity of recurrent lesions of DTC...
April 23, 2018: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/29650270/radioiodine-refractory-differentiated-thyroid-cancer
#5
REVIEW
Yuchen Jin, Douglas Van Nostrand, Lingxiao Cheng, Min Liu, Libo Chen
Differentiated thyroid cancer (DTC) is usually curable with surgery, radioactive iodine (RAI), and thyroid-stimulating hormone (TSH) suppression. However, local recurrence and/or distant metastases occur in approximately 15% of cases during follow-up, and nearly two-thirds of these patients will become RAI-refractory (RR-DTC) with a poor prognosis. This review focuses on the most challenging and rapidly evolving aspects of RR-DTC, and we discuss the considerable improvement in more accurately defining RR-DTC, more effective therapeutic strategies, and describe the diagnosis, pathogenesis, and future prospects of RR-DTC...
May 2018: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29618578/pet-response-assessment-in-apatinib-treated-radioactive-iodine-refractory-thyroid-cancer
#6
Chen Wang, Xin Zhang, Xue Yang, Hui Li, Ruixue Cui, Wenmin Guan, Xin Li, Zhaohui Zhu, Yansong Lin
This work evaluated the use of the positron emission tomography/computed tomography (PET/CT) technique to assess the early therapeutic response and predict the prognosis of patients with radioactive iodine-refractory differentiated thyroid cancer (RAIR-DTC) who underwent apatinib therapy. Standardised uptake value (SUV), metabolic tumour volume (MTV) and total lesion glycolysis (TLG), derived from 18FDG PET/CT and SUV from 68Ga-NOTA-PRGD2 PET/CT, were evaluated. Tumour response was evaluated using the Response Evaluation Criteria in Solid Tumors (RECIST) 1...
April 4, 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29485411/response-of-retinoic-acid-in-patients-with-radioactive-iodine-refractory-thyroid-cancer-a-meta-analysis
#7
Kyoungjune Pak, Seunghyeon Shin, Seong-Jang Kim, In-Joo Kim, Samuel Chang, Phillip Koo, Jennifer Kwak, Jae-Ho Kim
PURPOSE: The purpose of this study was to evaluate the response of retinoic acid (RA) in radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). METHODS: Systematic searches of MEDLINE (from inception to December 2016) and of EMBASE (from inception to December 2016) were performed for English-language publications on thyroid cancer treated with RA. Studies were classified according to the response criteria used: (1) 123I or 131I whole body scintigraphy (WBS), (2) serum thyroglobulin (Tg) level, (3) the response evaluation criteria in solid tumors (RECIST) version 1...
2018: Oncology Research and Treatment
https://www.readbyqxmd.com/read/29467951/reverting-iodine-avidity-of-radioactive-iodine-refractory-thyroid-cancer-with-a-new-tyrosine-kinase-inhibitor-k905-0266-excavated-by-high-throughput-nis-sodium-iodide-symporter-enhancer-screening-platform-using-dual-reporter-gene-system
#8
Ji Min Oh, Senthilkumar Kalimuthu, Prakash Gangadaran, Se Hwan Baek, Liya Zhu, Ho Won Lee, Ramya Lakshmi Rajendran, Chae Moon Hong, Shin Young Jeong, Sang-Woo Lee, Jaetae Lee, Byeong-Cheol Ahn
Radioactive-iodine (RAI) therapy is typically unprevailing as anaplastic thyroid cancer (ATC) management, owing to the decrease in the endogenous sodium iodide symporter (NIS) expression. Therefore, new strategies for NIS re-induction are required to improve the efficacy of RAI therapy in ATC. In this study, we developed a novel high-throughput NIS enhancer screening platform using a dual reporter gene system to identify a potent tyrosine kinase inhibitor (TKI) and selected a new hit compound, K905-0266 TKI...
January 23, 2018: Oncotarget
https://www.readbyqxmd.com/read/29455653/novel-targeted-therapies-and-immunotherapy-for-advanced-thyroid-cancers
#9
REVIEW
George E Naoum, Michael Morkos, Brian Kim, Waleed Arafat
Thyroid cancer is a frequently encountered endocrine malignancy. Despite the favorable prognosis of this disease, 15-20% of differentiated thyroid cancer (DTC) cases and most anaplastic types, remain resistant to standard treatment options, including radioactive iodine (RAI). In addition, around 30% of medullary thyroid cancer (MTC) cases show resistance after surgery. The evolving understanding of disease-specific molecular therapeutic targets has led to the approval of two targeted therapies (Sorafenib and Lenvatinib) for RAI refractory DTC and another two drugs (Vandetanib and Cabozantinib) for MTC...
February 19, 2018: Molecular Cancer
https://www.readbyqxmd.com/read/29413688/predictive-factors-of-outcome-in-poorly-differentiated-thyroid-carcinomas
#10
Christelle de la Fouchardière, Myriam Decaussin-Petrucci, Julien Berthiller, Françoise Descotes, Jonathan Lopez, Jean-Christophe Lifante, Jean-Louis Peix, Anne-Laure Giraudet, Armelle Delahaye, Sandrine Masson, Claire Bournaud-Salinas, Françoise Borson Chazot
BACKGROUND: The prognosis of poorly differentiated thyroid carcinomas (PDTC) is heterogeneous though generally poor. The objectives of this study were to identify clinical and molecular factors of poor prognosis. METHODS: One hundred four consecutive patients treated for a PDTC between 01/01/2000 and 31/12/2010 were included in this study. A pathological review was done for all cases (blinded to clinical data and outcome). RESULTS: All patients underwent thyroidectomy...
March 2018: European Journal of Cancer
https://www.readbyqxmd.com/read/29399055/refractory-thyroid-carcinoma-which-systemic-treatment-to-use
#11
REVIEW
Laurence Faugeras, Anne-Sophie Pirson, Julian Donckier, Luc Michel, Julien Lemaire, Sebastien Vandervorst, Lionel D'Hondt
The incidence of thyroid cancer has increased markedly in recent decades, but has been stable in terms of mortality rates. For the most part, these cancers are treated with surgery, which may or may not be followed by radioactive iodine depending on the tumor subtype. Still, many of these cancers will recur and may be treated with radioactive iodine or another surgery. It is unclear what treatment is best for cases of locally advanced or metastatic thyroid cancer that are refractory to radioactive iodine. Chemotherapy has a very low response rate...
2018: Therapeutic Advances in Medical Oncology
https://www.readbyqxmd.com/read/29350109/tertiary-care-experience-of-sorafenib-in-the-treatment-of-progressive-radioiodine-refractory-differentiated-thyroid-carcinoma-a-korean-multicenter-study
#12
Mijin Kim, Tae Hyuk Kim, Dong Yeob Shin, Dong Jun Lim, Eui Young Kim, Won Bae Kim, Jae Hoon Chung, Young Kee Shong, Bo Hyun Kim, Won Gu Kim
BACKGROUND: Sorafenib, a multi-kinase inhibitor, is approved for the treatment of patients with radioactive iodine (RAI)-refractory differentiated thyroid cancer (DTC). This study evaluated the efficacy and safety of sorafenib in real-world clinical practice and compared the results to those of the DECISION trial. The clinical features associated with better clinical outcomes after sorafenib treatment were also evaluated. METHODS: This multicenter, retrospective cohort study evaluated 98 patients with progressive RAI-refractory DTC who were treated with sorafenib in six tertiary hospitals in Korea...
March 2018: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29317481/iaps-cause-resistance-to-trail-dependent-apoptosis-in-follicular-thyroid-cancer
#13
Thomas A Werner, Inga Nolten, Levent Dizdar, Jasmin C Riemer, Sina C Schütte, Pablo E Verde, Katharina Raba, Matthias Schott, Wolfram T Knoefel, Andreas Krieg
Follicular thyroid cancer's (FTC) excellent long-term prognosis is mainly dependent on postoperative radioactive iodine (RAI) treatment. However, once the tumour becomes refractory, the 10-year disease-specific survival rate drops below 10%. The aim of our study was to evaluate the prognostic and biological role of the TRAIL system in FTC and to elucidate the influence of small-molecule-mediated antagonisation of inhibitor of apoptosis proteins (IAPs) on TRAIL sensitivity in vitro Tissue microarrays were constructed from forty-four patients with histologically confirmed FTC...
March 2018: Endocrine-related Cancer
https://www.readbyqxmd.com/read/29302491/an-ectopic-intrathyroidal-thymic-tissue-and-intrathymic-parathyroid-tissue-in-a-patient-with-graves-disease
#14
Kelly O'Connor, Hassan Alzahrani, Fadi Murad, Philip Daroca, Emad Kandil
Ectopic intrathyroidal thymic tissue, with coinciding intrathymic parathyroid tissue, is a very rare occurrence that is most often found incidentally in adults during surgery. We report a 23-year-old female who presented with Graves disease refractory to medical treatment. Radioactive iodine uptake demonstrated increased, diffuse uptake in the region of the thyroid. The patient underwent a total thyroidectomy and right inferior parathyroidectomy which was found enlarged intraoperatively. Histopathologically, surgical specimen demonstrated characteristics of intrathyroidal thymic tissue and intrathymic parathyroid tissue...
December 2017: Gland Surgery
https://www.readbyqxmd.com/read/29301825/genomic-correlates-of-response-to-everolimus-in-aggressive-radioiodine-refractory-thyroid-cancer-a-phase-ii-study
#15
Glenn J Hanna, Naifa L Busaidy, Nicole G Chau, Lori J Wirth, Justine A Barletta, Antonio Calles, Robert I Haddad, Stefan Kraft, Maria E Cabanillas, Guilherme Rabinowits, Anne O'Neill, Sewanti A Limaye, Erik K Alexander, Francis D Moore, Krystof Misiwkeiwicz, Tom Thomas, Matthew Nehs, Ellen Marqusee, Stephanie L Lee, Pasi A Jänne, Jochen H Lorch
Purpose: Targeting mutations leading to PI3K/mTOR/Akt activation are of interest in thyroid cancer. We evaluated the efficacy of everolimus in aggressive, radioactive iodine-refractory (RAIR) thyroid cancer and correlated tumor mutational profiling with response. Exploratory medullary and anaplastic thyroid cancer cohorts were included. Experimental Design: This single-arm, multi-institutional phase II study was conducted from 2009 to 2013 in patients with incurable RAIR thyroid cancer who had radiographic progression six months prior to enrollment...
April 1, 2018: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/29262462/-progress-in-diagnosis-and-treatment-of-radioactive-iodine-refractory-differentiated-thyroid-carcinoma
#16
REVIEW
Z Zhao, G H Shen, Y H Li, K Zhou, H W Cai
The radioactive iodine-refractory differentiated thyroid carcinoma (RIR-DTC) is a complex process that involves multiple genetic changes and multiple signaling pathways.Radionuclide imaging, genomics and proteomics are effective to clarify the mechanism and helpful in clinical diagnosis and therapy.The treatment of RIR-DTC includes the removal of distant metastases, drug therapy, external radiotherapy and radiofrequency ablation.This review mainly focuses on the pathogenesis, diagnosis and treatment of RIR-DTC...
December 7, 2017: Zhonghua Er Bi Yan Hou Tou Jing Wai Ke za Zhi, Chinese Journal of Otorhinolaryngology Head and Neck Surgery
https://www.readbyqxmd.com/read/29243843/signaling-cascades-in-thyroid-cancer-increasing-the-armory-of-archers-to-hit-bullseye
#17
Faiza Abdul Rashid, Qaisar Mansoor, Sobia Tabassum, Hafsa Aziz, Waleed O Arfat, George E Naoum, Muhammad Ismail, Ammad Ahmad Farooqi
Thyroid cancer is a multifaceted and therapeutically challenging disease and rapidly accumulating experimentally verified findings have considerably improve our understanding of the molecular mechanisms which underlie its development. Substantial fraction of information has been added into existing landscape of molecular oncology and we have started to develop a sharper understanding of the underlying mechanisms of thyroid cancer. Wealth of information demystified different intracellular signaling cascades which are frequently deregulated in thyroid cancer...
December 15, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29209273/updates-on-the-management-of-advanced-metastatic-and-radioiodine-refractory-differentiated-thyroid-cancer
#18
REVIEW
Dario Tumino, Francesco Frasca, Kate Newbold
Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating hormone suppressive therapy. However, 5-10% of patients have advanced disease, with aerodigestive tract invasion, distant metastases, or radioiodine refractory disease, with poor prognosis. This review focuses on the approaches for treating advanced DTC, including management of gross extra-thyroidal extension, recurrent loco-regional or distant metastatic disease, the role of external beam radiation therapy and systemic treatment...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29162036/sorafenib-treatment-for-papillary-thyroid-carcinoma-with-diffuse-lung-metastases-in-a-child-with-autism-spectrum-disorder-a-case-report
#19
Yousuke Higuchi, Takayuki Motoki, Hisashi Ishida, Kiichiro Kanamitsu, Kana Washio, Takanori Oyama, Takuo Noda, Yasuko Tsurumaru, Ayumi Okada, Hirokazu Tsukahara, Akira Shimada
BACKGROUND: Pediatric papillary thyroid carcinoma frequently presents with lymph node involvement and distant metastases. Sorafenib, an oral multikinase inhibitor, has been used to treat radioactive iodine (RAI) therapy-refractory thyroid carcinoma in adults; however, pediatric experience is limited. Medical procedures and hospitalization for children with autism spectrum disorder may be challenging. CASE PRESENTATION: An 11-year-old boy with autism spectrum disorder and moderate intellectual impairment presented with dyspnea on exertion with thyroid carcinoma and diffuses lung metastases...
November 21, 2017: BMC Cancer
https://www.readbyqxmd.com/read/29092022/pulmonary-metastasectomy-for-thyroid-cancer-as-salvage-therapy-for-radioactive-iodine-refractory-metastases
#20
Isabelle Moneke, Jussuf T Kaifi, Raphael Kloeser, Patrick Samson, Benedikt Haager, Sebastian Wiesemann, Sven Diederichs, Bernward Passlick
OBJECTIVES: Distant metastasis arising from thyroid cancer is rare but has been associated with significantly reduced long-term survival, especially when refractory to radioactive iodine ablation. We provide one of the largest studies worldwide reporting the outcome after salvage pulmonary metastasectomy for this entity, aiming to identify prognostic factors and to analyse surgical indication. METHODS: We retrospectively analysed the medical records of 43 patients who had undergone pulmonary metastasectomy for radioactive iodine-refractory thyroid cancer from 1985 to 2016...
March 1, 2018: European Journal of Cardio-thoracic Surgery
keyword
keyword
117482
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"